1. PETER J. OATES, Ph.D.
Oates Biomedical Consulting, LLC
16 Ferry View Drive
Gales Ferry, Connecticut 06335 USA
1-860-625-4832
oatespj@comcast.net
PROFESSIONAL HISTORY

CEO and Chief Scientific Officer, Oates Biomedical Consulting, LLC, 2009- present
– Diabetes & its complications, esp. nephropathy, neuropathy, ocular and vascular complications
– Drug development in areas such as diabetes, obesity, cardiovascular and neurological disease
– Seminars and consultations nationally and internationally to Pharmas and academic groups

Director, Diabetes and Diabetic Complications, Stealth Peptides Inc., Newton Centre, MA,
2012- present
– Assisting worldwide development of first-in-class mitochondrial protectant BendaviaTM for
ocular, vascular and renal diseases

Pizer Inc., 1979-2008
Pfizer Global Research and Development
Department of Cardiovascular, Metabolic and Endocrine Diseases
Groton, Connecticut 06340 USA

Research Fellow, 2004-2008, Diabetes Translational Pharmacology
– Researched drugs for the treatment of diabetes
– Researched drugs for preventing and arresting the complications of diabetes

Research Advisor, 1998-2003, Diabetic Complications
– Researched drugs, e.g., aldose reductase inhibitors (ARIs), for the complications of diabetes

Principal Research Investigator, 1992-97, Diabetic Complications
– Supported clinical studies (nerve, kidney, heart) with phase II/III ARI zopolrestat
1
P. J. Oates

2. – Helped identify a sorbitol dehydrogenase inhibitor for probing the role of the polyol pathway
– Fruitful collaborations with leading U.S. & overseas academic laboratories in this field

Senior Research Investigator, 1986-91, Diabetic Complications
– Proposed and established a rat model of diabetic renal hyperperfusion
– Developed innovative laser Doppler methodology to measure renal hyperperfusion
– Showed ARIs reversed renal hyperperfusion, activity later shown in human diabetics

Project Leader, 1982-85, Gastrointestinal Research Group
– Responsibility for Pfizer's GI research group (4 Ph.D.s, 10 staff members)
– Proposed new model of gastric mucosal barrier, the “Homeostat model”
– Published first model for pathogenesis of ethanol-induced gastric lesions
– Proposed and identified the first “cytoprotective” H2-antagonist

Senior Research Scientist, 1981, Gastrointestinal Research Group
– Supervised the Gastrointestinal Disease Research Group (five staff members)
– Identified zaltidine, an orally potent histamine H2-antagonist
– Aided commercial development of zaltidine, a potent histamine H2-antagonist

Research Scientist, 1979-81, Gastrointestinal Research Group
– Studied GI effects of prostaglandins, obtained new insights into “cytoprotection”
EDUCATION

Postdoctoral Research Fellow, 1975-79, Vanderbilt University
– Department of Molecular Biology, Nashville, Tennessee with Dr. Oscar Touster
– Dr. Chaim Weizmann Postdoctoral Fellowship, 1976-77, 1977-78, 1978-79;
awarded by California Institute of Technology on a nationally competitive basis
– Discovered ATP/GTP and cAMP/cGMP regulated lysosome fusion in vitro
2
P. J. Oates

3. 
Ph.D. in Molecular Biology, 1969-75, Vanderbilt University
Department of Molecular Biology, Nashville, Tennessee with Dr. Oscar Touster
– Minors, Biochemistry and Physiology. G.P.A., 3.0/3.0
– NIH Predoctoral Fellowship, 1969-75
– Developed the first experimental system in which lysosomes fused in vitro
– Invented novel light and electron micrographic assays to measure lysosome fusion

B.S. in Chemistry and Philosophy cum laude, 1965-69, Boston College
Chestnut Hill, Massachusetts. American Chemical Society certified
INVITED ORAL PRESENTATIONS
Neurology Grand Round, Department of Neurosciences, Winthrop University Hospital, “Chronic
Complications of Diabetes and the Polyol Pathway: Lessons Learned and a New Paradigm.” Mineola,
New York, June 28, 2013
Stealth Peptides Inc., “Potential for a Mitochondrial Protectant in Diabetic Kidney Disease,” Boston,
Massachusetts, May 16, 2013
Stealth Peptides Inc., “Diabetic Retinopathy: Sources of Oxidative Stress,” Boston, Massachusetts, April
8, 2013
Connecticut College, Medicinal Chemistry 300 Course lectures, “Pharmacological Approaches to
Diabetes Management” and “Pharmacological Approaches to Reducing the Long Term Complications of
Diabetes.” New London, Connecticut, November 7, 2012
Instituto Oftalmológico Fernández-Vega, “The Polyol Pathway and Diabetic Eye Disease: Progress from
Test Tube to Clinic.” Oviedo, Spain, October 8, 2012
Boehringer Ingelheim Pharmaceuticals, Inc., “Diabetic Kidney Disease: Mechanisms, Models and
Biomarkers.” Ridgefield, Connecticut, August 25, 2011
Bach Pharma Inc., Scientific Advisory Board Meeting, “Chronic Complications of Diabetes: The
Pathogenic Role of the Polyol Pathway and Oxidative Stress.” Merrimack College, North Andover,
Massachusetts, April 9, 2011
Connecticut College, Medicinal Chemistry 300 Course, “Diabetes, Insulin and Diabetic Complications.”
New London, Connecticut, November 17, 2010
St-Boniface Hospital, Division of Neurodegenerative Disorders, and University of Manitoba, Department
of Pharmacology and Therapeutics, “Chronic Complications of Diabetes Mellitus and the Polyol
Pathway: Pharmacology 301.” Winnipeg, Canada, June 11, 2010
3
P. J. Oates

4. University of California San Diego, Department of Pathology, “Diabetic Kidney Disease and the Polyol
Pathway: Lessons Learned and a New Paradigm.” La Jolla, California, November 2, 2009
Pfizer Global Research and Development, Department of Cardiovascular, Endocrine and Metabolic
Diseases, “Diabetic Nephropathy: Overview, Mechanisms and Models.” Groton, Connecticut, August 27,
2009
Connecticut College, Medicinal Chemistry 300 Course, “Diabetes and Its Long Term Complications.”
New London, Connecticut, November 19, 2008
Cambridge Healthtech Institute's Sixth Annual Symposium, Discovery On Target, Targeting Diabetes
with Novel Therapeutics, Session chair and “Diabetic Complications and the Polyol Pathway: Lessons
Learned and A New Paradigm,” Boston, Massachusetts, October 23, 2008
International Conference, N.I.D.D.K.D.-J.D.R.F. Consensus Conference on Indices of Diabetic
Neuropathy in Preclinical Models, opening lecture, “What Drug Development Needs from Preclinical
Models,” Orvieto, Italy, September 3, 2008
International Conference, Diabetic Complications 2007: The Role of Aldose Reductase and Related
Pathways, “Chronic Treatment with Aldose Reductase Inhibitor Zopolrestat Suppressed Sorbitol,
But Not Fructose, in Sural Nerves of Patients with Diabetic Neuropathy.” Kona, Hawaii, March 28,
2007
International Conference, Diabetic Complications 2007: The Role of Aldose Reductase and Related
Pathways, “An Aldose Reductase Inhibitor of A New Structural Class Prevents or Reverses Early Retinal
Abnormalities in Experimental Diabetic Retinopathy.” Kona, Hawaii, March 27, 2007
Pennington Biomedical Research Symposium, Louisiana State University System, Diabetic
Complications, “Diabetic Complications and the Polyol Pathway: A New Paradigm.” Baton Rouge,
Louisiana, January 29, 2007
Connecticut College, Medicinal Chemistry 300 Course, “Biochemical Aspects of Diabetes and Its
Complications.” New London, Connecticut, September 27, 2006
Pfizer Creve Coeur Labs, Pfizer Global Research and Development, “Diabetic Nephropathy,
Hypertension and the Polyol Pathway.” St. Louis, Missouri, May 25, 2006
Pfizer Chesterfield Labs, Pfizer Global Research and Development, “A Few Lessons in Enzyme Kinetics
from the Polyol Pathway.” St. Louis, Missouri, April 4, 2006
Research Technology Center, Pfizer Global Research and Development, “Concept to Phase 2A:
ARI CP-744809 for Diabetic Nephropathy.” Boston, Massachusetts, February 22, 2006
Pfizer La Jolla Labs, Pfizer Global Research and Development, “Aldose Reductase Inhibitors and the
Chronic Complications of Diabetes Mellitus: New Paradigms.” La Jolla, California, April 22, 2005
The Conway Institute, University College Dublin, “Diabetic Complications and the Polyol Pathway: A
New Paradigm for an Old Pathway.” Dublin, Ireland, November 15, 2004
Cardiology Grand Rounds, Department of Medicine, Louisville School of Medicine, “The Polyol
Pathway and Cardiovascular Stress.” Louisville, Kentucky, May 26, 2004
4
P. J. Oates

5. International Polyol Pathway Conference, “Future Directions in Diabetic Complications Research.”
Kona, Hawaii, March 17, 2004
The Schepens Eye Institute and Department of Ophthalmology, Harvard Medical School, “Diabetic
Complications and the Polyol Pathway: New Paradigms.” Boston, Massachusetts, February 17, 2004
National Institutes of Health Symposium, Diabetic Complications: Progress Through Animal Models,
“Aldose Reductase Inhibition: New Paradigms.” Bethesda, Maryland, October 20, 2003
Department of Pharmaceutical Sciences, University of Nebraska Medical Center, “Aldose Reductase
Inhibitors: New Insights on Mechanism of Action and Clinical Applications Outcomes.” Omaha,
Nebraska, April 30, 2003
Endocrine Grand Rounds, Brown Medical School, Rhode Island Hospital, “Aldose Reductase Inhibitors:
New Insights on Mechanism of Action and Clinical Applications Outcomes.” Providence, Rhode Island,
March 19, 2003
The Schepens Eye Institute and Department of Ophthalmology, Harvard Medical School, “The Polyol
Pathway and the Long Term Complications of Diabetes Mellitus.” Boston, Massachusetts, March 18,
2003
Discovery Technology Center, Pfizer Global Research and Development, “Orally Active, Low Nanomolar Inhibitors of Sorbitol Dehydrogenase and of Aldose Reductase: From Concept to CANs.”
Cambridge, Massachusetts, February 12, 2003
American Diabetes Association Symposium Neuropathy as a Vascular Complication, “Diabetic
Neuropathy: Evidence for Metabolic Causation.” San Francisco, California, June 14, 2002.
First International Symposium on Diabetic Complications: Diabetic Neuropathy, “Diabetic Neuropathy
and the Polyol Pathway.” Hong Kong, People's Republic of China, May 11, 2002
International Diabetes Federation Congress, WPR, “Pathways of Hyperglycemic Damage and Their
Interactions: New Insights.” Beijing, People's Republic of China, May 6, 2002
Department of Molecular Medicine, University of Plymouth Medical School, “The Polyol Pathway and
the Long Term Complications of Diabetes Mellitus.” Plymouth, United Kingdom, September 14, 2001
Center for Diabetic Complications, Columbia University College of Physicians & Surgeons, “The Polyol
Pathway and the Long Term Complications of Diabetes Mellitus.” New York, New York, March 9, 2001
Department of Cell and Molecular Biology Seminar Series, University of Connecticut, “New Evidence
from Human Molecular Genetics Linking Polyol Pathway Metabolism to the Long Term Complications
of Diabetes,” Storrs, Connecticut, September 28, 2000
XXXII International Congress, Hard to Treat Chronic Diseases, “Aldose Reductase Inhibitors, Diabetic
Neuropathy, and Diabetic Nephropathy,” Baltimore, Maryland, September 24, 1999
Fourth Toronto-Stockholm Symposium on Perspectives in Diabetes Research, New Aspects of
Pathogenesis and Treatment of Diabetes Mellitus, “Aldose Reductase Inhibitors,” Stockholm, Sweden,
July 6, 1999
5
P. J. Oates

6. IBC Conference, Fibrosis, “Fibrosis in the Diabetic Kidney and Aldose Reductase Inhibitors,” Boston,
Massachusetts, September 18, 1998
Pfizer Neuropathy Forum, “Diabetic Neuropathy and Polyol Pathway Inhibitors,” London, United
Kingdom, September 3, 1998
Pfizer Inc., “Aldose Reductase Inhibitors and Diabetic Neuropathy and Nephropathy,” Sandwich, Kent,
United Kingdom, March 10, 1998
International Diabetes Federation Congress and EASD Diabetic Neuropathy Study Group, 4th
International Symposium on Diabetic Neuropathy, “The Polyol Pathway -- A Culprit in Diabetic
Neuropathy?” Amsterdam, The Netherlands, July 15, 1997
IBC Conference, Molecular Targets for the Treatment of Chronic Renal Failure, “Aldose Reductase
Inhibitors, Renal Hemodynamics and Diabetic Nephropathy.” Boston, Massachusetts, March 11, 1997
American Diabetes Association, Hartford Affiliate Regional Meeting, “Diabetes: Therapeutic Progress
and Current Research.” Rocky Hill, Connecticut, October 8, 1996
Zopolrestat European Advisory Board, “Preclinical Zopolrestat Nephropathy Data.” Baden Bei Wien,
Austria, August 30, 1996
Pathology Institute and Department of Internal Medicine, “Aldose Reductase Inhibitors and the Long
Term Microvascular Complications of Diabetes Mellitus.” Kommunehospitalet, Århus, Denmark,
August 28, 1996
Zopolrestat US Advisory Board, “Electrophysiology and Clinical Endpoints.” Boston, Massachusetts,
July 15, 1996
William Harvey Research Conference, Diabetic Complications as Drug Targets, “Aldose Reductase
Inhibitors.” London, United Kingdom, May 31, 1996
Harvard Medical School, Deaconess Hospital, “The Polyol Pathway and the Microvascular
Complications of Diabetes Mellitus.” Boston, Massachusetts, April 10, 1996
Zopolrestat International Advisory Board, “Zopolrestat: New Preclinical Development Research and
Potential Future Clinical Research.” Saltsjöbaden, Sweden, September 9, 1995
National Institutes of Health, National Eye Institute, “Sorbitol Dehydrogenase and Diabetic
Complications.” Bethesda, Maryland, May 3, 1995
Connecticut College Medicinal Chemistry 300, “Diabetes and Diabetic Complications -- Therapeutic
Approaches.” Groton, Connecticut, October 27, 1994
Connecticut College, Department of Chemistry 1994-95 Seminar Series, “Diabetes: Therapeutic Progress
and Unsolved Mysteries.” New London, Connecticut, October 4, 1994
United States-Japan Aldose Reductase Workshop, “What is the Relationship between Aldose Reductase,
Sorbitol Dehydrogenase and Diabetic Complications?” Introductory Remarks as Session Chair, Kona,
Hawaii, February 21, 1994
6
P. J. Oates

7. Zopolrestat Investigators' Meeting, Diabetic Nephropathy (Protocol 078-106): “Zopolrestat: Pre-Clinical
Animal Pharmacology.” West Palm Beach, Florida, February 28, 1994
Harvard Medical School and the Joslin Diabetes Center Symposium, Vascular Complications of Diabetes
Mellitus, “Vascular Effects of Aldose Reductase Inhibitors.” Cambridge, Massachusetts, October 8, 1993
The 1993 East Coast Cardiovascular Discussion Group Symposium, New Therapeutic Approaches to
NIDDM-Related Cardiovascular Disease, “Diabetic Nephropathy, Renal Hemodynamics and Aldose
Reductase Inhibitors.” Fairfield, New Jersey, October 4, 1993
American Diabetes Association, Connecticut Affiliate Regional Meeting, “Strategies to Prevent Diabetic
Kidney, Nerve and Eye Disease: Current Research.” East Lyme, Connecticut, May 12, 1993
Vanderbilt University, Departments of Hematology and Molecular Biology, “Biomedical Research
Opportunities in the Pharmaceutical Industry: A Personal Perspective.” Nashville, Tennessee, April 2,
1993.
Vanderbilt University, Department of Molecular Biology, “Diabetic Kidney Disease, Renal
Hemodynamics and the Polyol Pathway.” Nashville, Tennessee, April 1, 1993
Experimental Biology '93 Symposium, Laser Doppler Flowmetry in Biomedical Research, “Renal Blood
Flow in Hyperglycemic Rats.” New Orleans, Louisiana, March 31, 1993
UMDNJ-New Jersey Medical School, Department of Physiology, “Diabetic Kidney Disease, Renal
Hemodynamics and the Polyol Pathway.” Newark, New Jersey, January 22, 1993
Bowman Gray School of Medicine, Wake Forest University, Departments of Physiology and
Pharmacology, “Diabetic Kidney Disease, Renal Hemodynamics and the Polyol Pathway.” WinstonSalem, North Carolina, October 19, 1992
(Invited Oral Presentations prior to 1992 omitted to save space.)
OTHER ORAL PRESENTATIONS (1994-present)
International Conference, United Mitochondrial Disease Federation, Mitochondrial Medicine 2013,
“Bendavia, A Novel Peptide that Improves Mitochondrial Function and Reverses Diabetes Visual
Decline,” N M Alam, G T Prusky (presented by P J Oates), Newport Beach, California, June 12-15,
2013
Annual Meeting of the American Society of Nephrology, “Aldose Reductase Inhibitor Zopolrestat
Reduces Elevated Urinary Albumin Excretion Rate in Type 1 Diabetes Mellitus Subjects with Incipient
Diabetic Nephropathy,” P Oates, S Klioze, P Schwartz, A Boland and The Zopolrestat Diabetic
Nephropathy Study Group, Philadelphia, Pennsylvania, November 8, 2008
Annual Meeting of the European Association for the Study of Diabetes and of the EASD Diabetic
Neuropathy Study Group, “Chronic Treatment with Aldose Reductase Inhibitor Zopolrestat Suppressed
Sorbitol, But Not Fructose, in Sural Nerves of Patients with Diabetic Neuropathy.” P Oates, S Klioze,
and the Zopolrestat Diabetic Neuropathy Study Group. Utrecht and Amsterdam, The Netherlands,
September 16 and 19, 2007
7
P. J. Oates

8. International Conference, Diabetic Complications 2007: The Role of Aldose Reductase and Related
Pathways, “A Computer Model of Glucose Metabolism.” Kona, Hawaii, March 27, 2007
7th International Symposium on Diabetic Neuropathy and 19th World Diabetes Congress, International
Diabetes Federation, “Stronger Aldose Reductase Inhibition Is Required to Normalize Oxidative Stress
Marker GSSG / GSH than Sorbitol or Fructose in Diabetic Rat Nerve.” P J Oates, D A Beebe, C A Ellery
and J B Coutcher, Cape Town, South Africa, November 30 and December 4, 2006
American Diabetes Association Annual Meeting, “Inhibition of Aldose Reductase Improves the Ratio of
Oxidized Glutathione to Reduced Glutathione in the Blood of Diabetic Rats.” P Oates, D Beebe, C
Ellery, Washington, D.C., June 9-13, 2006
Annual Meeting of the European Association for the Study of Diabetes and of the EASD Diabetic
Neuropathy Study Group, “Aldose Reductase Inhibitors Prevent Hyperglycemia-Induced Alterations in
Cellular Glutathione and Redox Status at Drug Concentrations that are Similar and Higher than Required
to Normalize Cell Sorbitol.” P Oates, D Beebe, C Ellery, J Coutcher. Porto Heli, Greece, September 9,
2005
American Diabetes Association Annual Meeting, “Reduction of Elevated Urinary Albumin Excretion in
Diabetic Rats by Polyol Pathway Inhibitors Correlates with Changes in Urinary Sorbitol Excretion.” P
Oates, C Ellery, D Beebe, J Coutcher, Y-Z Qian, V Lowe and S O'Neill, San Diego, California, June 1112, 2005
Joint Meeting of the Diabetic Foot Study Group of the EASD and the Diabetic Neuropathy Study Group
of the EASD, “An Aldose Reductase Inhibitor of a New Structural Class, Pyridazinone: In Vitro and Oral
Activity Profile of CP-744809 in Diabetic Rat Sciatic Nerve.” P J Oates, J B Coutcher, D A Beebe, C
A Ellery and B L Mylari. Regensburg, Germany, September 3, 2004
Annual Meeting of the European Association for the Study of Diabetes, “Sorbitol Dehydrogenase
Inhibition As Well As Aldose Reductase Inhibition Prevents Elevation Of Urinary Albumin Excretion In
Diabetic Rats.” P Oates, C Ellery, D Beebe, J Coutcher, Y-Z Qian, D Phillips, V Lowe, T Appleton, D
Raunig, S O'Neil, B Mylari. Munich, Germany, September 7, 2004
International Polyol Pathway Conference, “In Vitro and Oral Activity of Sorbitol Dehydrogenase
Inhibitor CP-642931 in Streptozocin Diabetic Rats.” P Oates, J Coutcher, C Ellery, Y-Z Qian, D Phillips,
V Lowe, T Appleton, D Beebe, D Raunig, S O’Neil and B Mylari. Kona, Hawaii, March 14, 2004
International Polyol Pathway Conference, “Determination of The Equilibrium Dissociation Constant
of Aldose Reductase Inhibitor CP-744809 for Human Aldose Reductase.” P Oates, D Beebe, and B
Mylari. Kona, Hawaii, March 16, 2004
Annual Department of Molecular and Cell Biology Retreat, University of Connecticut (Storrs),
“Determination of the Equilibrium Dissociation Constant of Aldose Reductase Inhibitor
CP-744809 for Human Aldose Reductase.” D Beebe, B Mylari and P Oates. Hebron, Connecticut,
September 6, 2003
Annual Meeting of the European Association for the Study of Diabetes and the Neurodiab Meeting,
“Models of Normal and Neuropathic Diabetic Human Sural Nerves and Their Sorbitol Contents.” P J
Oates, D A Beebe, J B Coutcher, C A Ellery and the Zopolrestat Diabetic Neuropathy Study Group. Paris
and St. Malo, France, August 29 and 30, 2003
8
P. J. Oates

9. Neurodiab Meeting and 38th Annual Meeting of the European Association for the Study of Diabetes,
“Quantitation of Polyol Pathway Enzymes in Normal and Diabetic Rat Sciatic Nerve.” P J Oates, C A
Ellery, D A Beebe and J B Coutcher. Aberdeen, Balontonfüred, Hungary, September 30, and Budapest,
Hungary, September 4, 2002
American Diabetes Association Annual Meeting, “Oxidative Stress Marker Urinary 8Hydroxydeoxyguanosine Is Chronically Elevated in Diabetic Rats.” P J Oates, C A Ellery, D A
Beebe and J B Coutcher. San Francisco, California, June 15, 2002
Neurodiab Meeting and 37th Annual Meeting of the European Association for the Study of Diabetes, “A
Metabolic Model of Rat Sciatic Nerve Sorbitol.” P J Oates, C A Ellery, D A Beebe and J B Coutcher.
Aberdeen, U.K., September 8, and Glasgow, U.K., September 14, 2001
American Diabetes Association Annual Meeting, “A Metabolic Model of Sorbitol in Normal and
Diabetic Peripheral Nerve,” P J Oates, C A Ellery, D A Beebe and J B Coutcher. Philadelphia, June 23,
2001
The 36th Annual Meeting of the European Association for the Study of Diabetes, “VEGF
Immunoreactivity Is Reduced in Serum and Plasma of Zopolrestat-treated Diabetic Rats,” P J Oates and
C A Ellery. Jerusalem, Israel, September 18, 2000
US-Japan Aldose Reductase Workshop, “Aldose Reductase Inhibition with Zopolrestat Reduces
Ischemic Myocardial Injury in the Rabbit Heart,” W. Ross Tracey, William P. Magee, Craig A. Ellery,
Joseph T. MacAndrew, Andrew H. Smith, Delvin R. Knight and Peter J. Oates. Kona, Hawaii, January
24, 2000
US-Japan Aldose Reductase Workshop, “Determination of Equilibrium Dissociation Constant for TightBinding Aldose Reductase Inhibitor Zopolrestat,” Peter J Oates, David Beebe, Banavara Mylari and
Charles Grimshaw. Kona, Hawaii, January 25, 2000
European Association for the Study of Diabetes Annual Meeting, “Reversal of Galactose-induced Renal
Hyperperfusion in Rats by Aldose Reductase Inhibitor Zopolrestat,” C A Ellery and P J Oates. Brussels,
Belgium, August 31, 1999
The Fourth Toronto-Stockholm Symposium on New Perspectives in Diabetes Research, “Dose-dependent
Preservation of Nerve Function in Diabetic Rats with Inhibition of Either Step of the Polyol Pathway,” P
Oates, T Schelhorn, M Miller, E Hammerlund, C Ellery, D Beebe and J Hakkinen. Stockholm, Sweden,
July 5, 1999
American Diabetes Association Annual Meeting, “Inhibitors of Sorbitol Dehydrogenase (SDI) and
Aldose Reductase (ARI) Reverse Impaired Motor Nerve Conduction Velocity (MNCV) in Diabetic
Rats,” Y Ido, K Chang, P Oates, B Mylari and J Williamson. San Diego, California, June 19, 1999
American Diabetes Association Annual Meeting, “Reversal of Hyperglycemia-induced PKC Activation,
Intracellular AGE Formation, and Sorbitol Accumulation by Inhibition of Electron Transport Complex
II,” M A Brownlee, T Nishikawa, D Edelstein, I Giardino, D Beebe and P J Oates. San Diego,
California, June 20, 1999
Neurodiab Meeting and 34th EASD Meeting, “Polyol Pathway Inhibitors Dose-Dependently Preserve
Nerve Function In Diabetic Rats,” P Oates, T Schelhorn, M Miller, E Hammerlund, C Ellery, D Beebe
9
P. J. Oates

10. and J Hakkinen. Sitges, Spain, September 5-7, 1998, and Barcelona, Spain, September 8-12, 1998
International Diabetes Federation Meeting, “Alond™ Reduces High Urinary Albumin Excretion But Not
Blood Pressure in Conscious Diabetic Rats.” P Oates and C Ellery. Helsinki, Finland, July 20-25, 1997
Annual Department of Molecular and Cell Biology Retreat, University of Connecticut (Storrs), “The
Kinetic Mechanism of Sorbitol Dehydrogenase.” D Beebe and P Oates. Hebron, Connecticut, October
14, 1996
European Association for the Study of Diabetes Annual Meeting, “Glycolytic Pathway, Redox State of
NAD-Couples, and Energy Metabolism in Lenses in Rats with Short-Term Diabetes.” P J Oates, T
Nakano, J M Petrash, J R Williamson and I Obrosova. Vienna, Austria, September 2-6, 1996
Association for Research in Vision & Ophthalmology Annual Meeting, “The Effect Of Sorbitol
Dehydrogenase Inhibition On Sugar Cataract Formation In Cultured Rat Lens.” P J Oates, J B Coutcher,
and B L Mylari. Ft. Lauderdale, Florida, April 22, 1996
European Association for the Study of Diabetes 31st Annual Meeting, “Peripheral Neuropathy In
Diabetic Rats Is Prevented By Inhibition Of Sorbitol Dehydrogenase Or Aldose Reductase.” P Oates, Y
Ido, B Mylari, J Williamson. Stockholm, Sweden, September 16, 1995
Association for Research in Vision & Ophthalmology Annual Meeting, “Inhibition of Sorbitol
Dehydrogenase Prevents Increased Retinal Vascular Albumin Permeation in Diabetic But Not in
Galactosemic Rats.” P Oates, B Mylari, K Chang, and J Williamson. Ft. Lauderdale, Florida, May 19,
1995
International Diabetes Federation Congress, “Diabetes-Induced Vascular Dysfunction Is Prevented by
Inhibition of Sorbitol Dehydrogenase.” P Oates, B Mylari, K Chang, D Beebe, J Coutcher, T Siegel, W
Zembrowski and J Williamson. Kobe, Japan, November 6, 1994
United States-Japan Aldose Reductase Workshop, “Reversal of Albuminuria in Diabetic Rats by Aldose
Reductase Inhibitor Zopolrestat.” P J Oates and C A Ellery. Kona, Hawaii, February 19, 1994
(Presentations prior to 1994 omitted.)
COMMITTEE MEMBERSHIPS

Juvenile Diabetes Research Foundation Key Opinion Leader Panel, “The State of Diabetic
Complications in Type 1 Diabetes,” New York, NY, September 10-11, 2012

Juvenile Diabetes Research Foundation Complications Therapies Strategic Research
Agreements FY2011 Committee, July 2010

Juvenile Diabetes Research Foundation Complications Therapies Cooperative Agreement
LOIs FY2010 Committee, May 2010

National Institutes of Diabetes and Digestive and Kidney Diseases and the Juvenile Diabetes
Research Foundation Consensus Group on Indices of Diabetic Neuropathy in Preclinical
Models, Biomarker Subcommittee Member, June 2008
10
P. J. Oates

11. 
Juvenile Diabetes Research Foundation, Co-Chair Grant Review Committee for Translational
Research in Diabetic Complications, New York, NY, 2007-09
– Scientific Chair, Translational Research Committee helping oversee ~ $10 million in JDRF funds

Pfizer CVMED Pancreatic Islet Core Team, Core Team Member, 2007-08
– Helping to critically analyze and standardize best procedures for islet preparation and use

Pfizer Global Diabetes Translational Research Team, Core Team Member, 2006-07
– Helping to analyze, identify and recommend strategy for key preclinical and clinical biomarkers

Organizing Committee, International Conference, “Diabetic Complications: Aldose Reductase
and Other Pathways,” Kona , HI, March 24-28, 2007
–

Co-Chair of Meeting and Scientific Program Chair
Pfizer Diabetes Research Candidate Management Team, Ad Hoc Member, 2006
– Helping to design preclinical and clinical studies to develop Pfizer drug candidates in humans

Groton Biology Scientific Advisory Board, Core Team Member, 2005-07
– Advising Pfizer Biology Council on scientific issues and policies

Diabetes Exploratory Project Review Committee, Member, Dec. 2005-07
– Helping to uncover and evaluate new drug targets for pursuit by new Pfizer research programs

Organizing Committee, “International Polyol Pathway Conference,” March 13-17, 2004
–

Co-Chair of Meeting and Scientific Program Chair
Pfizer Diabetic Complications Early Candidate Management Team (ECMT), 2004
– Helping to design studies to test and develop Pfizer drug candidates in humans

Pfizer Global Enzymology Network, Global Co-ordinator, 2008
–
–

Core Organizing Team, Co-cordinator, PGRD Groton site, 2004-2008
Helping to solve problems, identify best practices and develop course material for global rollout
Steering Committee, Pfizer Enzymology Course
–

Helped to design an enzymology course for Pfizer scientists at all global sites; 2004-2008
Member, External Advisory Board, RAGE Biology Program Project, Naomi Berrie
Diabetes Center at Columbia-Presbyterian Hospital, College of Physicians and
Surgeons of Columbia University, New York, NY 2002-2004
– Helping to assess and plan NIH-funded RAGE research for diabetic complications
11
P. J. Oates

12. 
Organizing Committee, US-Japan Aldose Reductase Workshop, Jan., 2000
–

Co-Chair of Meeting and Scientific Program Chair
Diabetic Complications Clinical Team (DCT), 1999-2003
– Helping to assess and plan Phase I-III strategies for testing and global registration of Pfizer drugs
HONORS & AWARDS

Recipient of an “Individual Performance Award,” “for going above and beyond expected
performance” and having “demonstrated exceptional performance and leader behaviors on a daily
basis.” PGRD, Diabetes Translational Pharmacology, Cardiovascular Metabolic and Endocrine
Diseases, October 30, 2008

Recipient of “Patriot Award,” Connecticut Committee for Employer Support of the Guard and
Reserve, Pfizer Global Research and Development, Groton, Connecticut, July 23, 2008
– Recognized for support of a lab member called to active duty and of Guard and Reserve values
– “Bosslift” via CH-47 helicopter, Stones Ranch/Camp Rell, Niantic, Connecticut, July 21, 2008

Recipient of “Patriotic Employer Award,” The National Committee for Employer Support of
the Guard and Reserve, Quonset Officer's Club, Quonset, Rhode Island, June 27, 2008
– Recognized for support of Guard and Reserve values and of a lab member called to active duty

Elected “Honorary Member” European Study Group for Diabetic Neuropathy, Utrecht, The
Netherlands, September 15, 2007
– “recognizes your major contributions to the scientific rigor of our organization”
– “unprecedented” for someone with a professional association with a pharmaceutical company

Interviewed in Pfizer research laboratory by CNN News Team, March 18, 2005
– Discussed Pfizer Diabetes Research program as part of CNN Profile of Pfizer; broadcast

Scientific Session Co-Chair, “Experimental Neuropathy,” American Diabetes Association
– Annual National Scientific Meeting, Orlando, Florida, June 6, 2004

Interviewed in-depth for Fast Company magazine article, June 2004 issue
– Described the nature of our diabetes research and the key importance of unshakeable persistence

Inductee, Xavier High School Hall of Fame, November 21, 2003
– Recognized for contributions to Church, regional communities and diabetes research

Member-of-the-Year, Pfizer Global R&D Diabetic Complications ECMT, 2003
12
P. J. Oates

13. – Provided leadership for planning and development of CAN compound for clinical use

Member-of-ECMT-Team-of-the-Year 2002, Pfizer Global
Metabolic Diseases, Diabetic Complications ECMT, 2002
R&D,
Cardiovascular
and
– Played a pivotal role in our Early Candidate Management Team (ECMT) in creation of a feasible
clinical plan forward to test potential clinical efficacy of two new classes of drugs to prevent or
slow the development of diabetic complications, e.g., diabetic nephropathy, neuropathy, and
retinopathy; plan endorsed by senior management

Member-of-ECMT-Team-of-the-Year 2002, Pfizer Global
Metabolic Diseases, Diabetic Complications ECMT, 2002

Member-of-the-Year, Pfizer Global R&D Diabetic Complications ECMT, 2001, 1993
R&D,
Cardiovascular
and
– Provided leadership for planning and development of two compounds for potential clinical use

Adjunct Professor, University of Connecticut
– Graduate Program in Molecular and Cell Biology, Storrs, CT, 1988 - 2008
– Associate Advisor for Christopher Kerantzas, candidate for Master of Science in Biochemistry,
The University of Connecticut Graduate School, Storrs, CT, 2007 - 2008

Adjunct Professor, Connecticut College
– Department of Chemistry, New London, CT, 1992 - present

Scientific Advisor, National Organization to Treat A-T (Ataxia telangiectasia, a severe
nervous and metabolic disorder, typically fatal in young adulthood)
– Austin, Texas, 1998 - 2005
PROFESSIONAL SOCIETIES

American Diabetes Association; manuscript reviewer for Diabetes

European Association for the Study of Diabetes; manuscript reviewer for Diabetologia

American Society of Nephrology

Association for Research in Vision and Ophthalmology

European Association for Vision and Eye Research

American Physiological Society

American Chemical Society

International Society of Nephrology

International Diabetes Federation, past member
13
P. J. Oates

14. 
New York Academy of Sciences, past member
PERSONAL

US Citizen, born New York, New York

Married; wife, Nancy J. (41 years); children: Peter M., Kathryn S.

Outside Activities
– SCUBA diving, Rescue Diver certification, 1995; swimming, basketball, hiking, history, travel
– Steering Committee for Norwich Diocesan Synod, 1989-92
– Coordinator, parish Small Christian Communities, Our Lady of Lourdes Church, 1992-2002
– Confirmation Teacher, RCIA, Our Lady of Lourdes Church, 1985-90
– Parish Eucharistic Minister, Our Lady of Lourdes Church, 1985-2002
St. Mary Star of the Sea Church, 2009 - 2010
REFERENCES

Available upon request
PUBLICATIONS

Book Chapters
Lorenzi, M and Oates PJ. “The Polyol Pathway and Diabetic Retinopathy.” In Contemporary Diabetes:
Diabetic Retinopathy, E. Duh, M.D., editor, The Humana Press Inc., Totowa, NJ, pp. 159-186, 2008
Ramasamy R and Oates PJ. “Aldose Reductase and Vascular Stress.” In Diabetes and Cardiovascular
Disease, D. Stern and S. Marso, eds., Lippincott Williams & Wilkins, Philadelphia, PA, pp. 55-74, 2004
PJ Oates, “Polyol Pathway and Diabetic Peripheral Neuropathy.” In International Review of
Neurobiology, 50, The Neurobiology of Diabetic Neuropathy. DR Tomlinson, ed., Academic Press,
London, pp. 325-392, 2002
PJ Oates. “Gastric Blood Flow and Mucosal Defence.” In Gastric Cytoprotection: A Clinician's Guide.
D Hollander and A Tarnowski, eds., Plenum Press, NY, pp. 125-165, 1989

Reviews
14
P. J. Oates

15. PJ Oates, “Aldose Reductase Inhibitors and Diabetic Kidney Disease.” Current Opinion in
Investigational Drugs, 11:402-417, 2010
PJ Oates, “Aldose Reductase, Still a Compelling Target For Diabetic Neuropathy.” Current Drug
Targets, 9: 14-36, 2008
PJ Oates and BL Mylari, “Aldose Reductase Inhibitors: Therapeutic Implications for Diabetic
Complications.” Expert Opinion on Investigational Drugs, 8:2095-2119, 1999
PJ Oates, “The Polyol Pathway -- A Culprit in Diabetic Neuropathy?”
Communications, 21: 33-40, 1997
Neuroscience Research
PJ Oates. “Diabetic Nephropathy, Renal Hemodynamics and Aldose Reductase Inhibitors.” Drug
Development Research, 32: 104-116, 1994
R Sarges and PJ Oates. “Aldose Reductase Inhibitors: Recent Developments.” Progress in Drug
Research, Birkhäuser Verlag, Basel, 40: 99-161, 1993
PJ Oates, D Papahadjopoulos, A Loyter. “Fusion and Implantation in Biological Membranes.” Trends in
Pharmacological Sciences, 3: 222-229, 1982

U.S. Patents
T A Beyer, D R Knight, Jr., B L Mylari, P J Oates, E R Pettipher, W R Tracey. “Method of Reducing
Tissue Damage Associated With Non-Cardiac Ischemia.” U.S. patent no. 6,127,367 issued October 3,
2000
T A Beyer, D R Knight, Jr., B L Mylari, P J Oates, E R Pettipher, W R Tracey. “Method of Reducing
Tissue Damage Associated With Ischemia; Administering Sorbitol Dehydrogenase Inhibitor.” U.S.
patent no. 5,932,581 issued August 3, 1999
B L Mylari, P J Oates, T W Siegel and W J Zembrowski. “Substituted Pyrimidines for the Control of
Diabetic Complications.” Field-of-use U.S. patent no. 5,866,578, issued February 2, 1999
B L Mylari, P J Oates, T W Siegel and W J Zembrowski. “Substituted Pyrimidines for the Control of
Diabetic Complications.” Field-of-use U.S. patent no. 5,728,704 issued March 17, 1998

Journal Articles
J A Pfefferkorn, A Guzman-Perez, P J Oates, J Litchfield, G Aspnes, A Basak, J Benbow, M A Berliner,
J Bian, C Choi, K Freeman-Cook, J W Corbett, M Didiuk, J R Dunetz, K J Filipski, W M Hungerford, C
S Jones, K Karki, A Ling, J-C Li, L Patel, C Perreault, H Risley, J Saenz, W Song, M Tu, R Aiello, K
Atkinson, N Barucci, D Beebe, P Bourassa, F Bourbounais, A M Brodeur, R Burbey, J Chen, T
D’Aquila, D R Derksen, N Haddish-Berhane, C Huang, J Landro, A L Lapworth, M MacDougall, D
Perregaux, J Pettersen, A Robertson, B Tan, J L Treadway, S Liu, X Qiu, J Knafels, M Ammirati, X
Song, P DaSilva-Jardine, S Liras, L Sweet and T P Rolph, “Designing Glucokinase Activators with
Reduced Hypoglycemia Risk: Discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-
15
P. J. Oates

16. carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a Clinical Candidate for the Treatment of
Type 2 Diabetes.” Medicinal Chemistry Communications, 2:828-839, 2011 doi: 10.1039/c1md00116g
H Liu, Y Luo, T Zhang, Y Zhang, Q Wu, L Yuan, S S M Chung, P J Oates and J Y Yang, “Genetic
Deficiency of Aldose Reductase Counteracts the Development of Diabetic Nephropathy in C57BL/6
Mice.” Diabetologia, 54: 1242-51, 2011
doi 10.1007/s00125-011-2045-4
P Xie, L Sun, P J Oates, S K Srivastava and Y S Kanwar, “Pathobiology of Renal Specific
Oxidoreductase/Myo-Inositol Oxygenase in Diabetic Nephropathy: Its Implications in Tubulo-Interstitial
Fibrosis.” American Journal of Physiology Renal Physiology, 298: F1393–F1404, 2010
doi: 10.1152/ajprenal.00137.2010
Z Landau, M J Novotny, G M Preston, K Wright, T Freeman, H Dai, J Thompson, P J Oates, and R A
Calle, “Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of a Novel Sorbitol
Dehydrogenase Inhibitor in Healthy Participants.” Journal of Clinical Pharmacology, 50: 521-530, 2010.
doi: 10.1177/0091270009336354
Y Ido, J R Nyengaard, K Chang, R G Tilton, C Kilo, B L Mylari, P J Oates and J R Williamson, “Early
Neuropathy and Vascular Dysfunction in Diabetic Rats Are Largely Sequelae of Increased Sorbitol
Oxidation.” Antioxidants and Redox Signaling, 12:39-51, 2010
J A Pfefferkorn, J Lou, M L Minich, K J Filipski, M He, R Zhou, S Ahmed, J Benbow, A-G Perez, M Tu,
J Litchfield, R Sharma, K Metzler, F Bourbonais, C Huang, D A Beebe, P J Oates, “Pyridones as
Glucokinase Activators: Identification of a Unique Metabolic Liability of the 4-sulfonyl-2-pyridone
Heterocycle.” Bioorganic & Medicinal Chemistry Letters, 19:3247-52, 2009
Q Li, Y Hwang, I Gomes, R Ananthakrishnan, P J Oates, D Guberski and R Ramasamy, “Polyol Pathway
and Modulation of Ischemia-Reperfusion Injury In Type 2 Diabetic BBZ Rat Hearts,” Cardiovascular
Diabetology, 7:33, 2008, doi:10.1186/1475-2840-7-33
B Yang, A Hodgkinson, P J Oates, B A Millward, and A G Demaine, “High Glucose Induction of DNAbinding Activity of the Transcription Factor NFB in Patients with Diabetic Nephropathy.” Biochim
Biophys Acta, Molecular Basis of Disease, 1782:295-302, 2008
L Qiu, X Wu, J F L Chau, I YY Szeto, W Y Tam, Z Guo, S K Chung, P J Oates, S S M Chung, and J Y
Yang, “Aldose Reductase Regulates Hepatic Peroxisome Proliferator-Activated Receptor-α
Phosphorylation and Activity to Impact Lipid Homeostasis.” Journal of Biological Chemistry, 283:
17175–17183, 2008
W Sun, P J Oates, J B Coutcher, C Gerhardinger and M Lorenzi, “A Selective Aldose Reductase
Inhibitor of a New Structural Class Prevents or Reverses Early Retinal Abnormalities in Experimental
Diabetic Retinopathy.” Diabetes, 55:2757-62, 2006
K Thamotharampillai, A K F Chan, B Bennetts, M Craig, J Cusumano, M Silink, P J Oates and K C
Donaghue, “Decline in Neurophysiological Function After 7 Years in an Adolescent Diabetic Cohort and
the Role of Aldose Reductase Gene Polymorphisms.” Diabetes Care, 29:2053-7, 2006
E C M Ho, K S L Lam, Y S Chen, J C W Yip, M Arvindakshan, S Yamagishi, S Yagihashi, P J Oates, C
A Ellery, S S M Chung and S K Chung, “Aldose Reductase Deficient Mice Are Protected from the
16
P. J. Oates

17. Delayed Motor Nerve Conduction and Increased JNK Activation, Depletion of Reduced Glutathione and
Increased Superoxide Accumulation and DNA Breaks.” Diabetes, 55: 1946-53, 2006
B Yang, A D Hodgkinson, P J Oates, H M Kwon, B A Millward and A G Demaine, “Elevated Activity of
Transcription Factor Nuclear Factor of Activated T-cells 5 (NFAT5) and Diabetic Nephropathy.”
Diabetes, 55:1450-55, 2006
B L Mylari, S J Armento, D A Beebe, E L Conn, J B Coutcher, M S Dina, M T O'Gorman, M C
Linhares, W H Martin, P J Oates, D A Tess, G J Withbroe and W J Zembrowski, “A Novel Series of
Non-Carboxylic Acid, Non-Hydantoin Inhibitors of Aldose Reductase with Potent Oral Activity in
Diabetic Rat Models: 6-(5-Chloro-3-methylbenzofuran-2-sulfonyl)-2h-pyridazin-3-one and Congeners.”
Journal of Medicinal Chemistry, 48:6326-39, 2005
R E Schmidt, D A Dorsey, L N Beaudet, C A Parvin, K E Yarasheski, S R Smith, J R Williamson, R G
Peterson, and P J Oates, “A Potent Sorbitol Dehydrogenase Inhibitor Exacerbates Sympathetic
Autonomic Neuropathy in Rats with Streptozotocin-induced Diabetes.” Experimental Neurology,
192:407-19, 2005
A K Changolkar, J A Hypolite, M Disanto, P J Oates, A J Wein and S Chacko, “Diabetes Induced
Decrease in Detrusor Smooth Muscle Force Is Associated with Oxidative Stress and Overactivity of
Aldose Reductase.” Journal of Urology 173:309-13, 2005
Y C Hwang, M Kaneko, S Bakr, H Liao, Y Lu, E R Lewis, S Yan, S Ii, M Itakura, L Rui, H Skopicki, S
Homma, A M Schmidt, P J Oates, M Szabolcs and R Ramasamy, “Central Role for Aldose Reductase
Pathway in Myocardial Ischemic Injury.” The FASEB Journal, 18:1192-1199, 2004
Y C Hwang, S Bakr, C Ellery, P J Oates, and R Ramasamy, “Sorbitol Dehydrogenase Inhibitors: A Novel
Therapeutic Intervention for Protecting Ischemic Myocardium.” The FASEB Journal, express article
10.1096/fj.03-0128fje. Published online October 2, 2003
B L Mylari, G J Withbroe, D A Beebe, N S Brackett, E L Conn, J B Coutcher, P J Oates, and W J
Zembrowski, “Design and synthesis of a novel family of triazine-based inhibitors of sorbitol
dehydrogenase with oral activity: 1-{4-[3R,5S-dimethyl-4-(4-methyl-[1,3,5]triazin-2-yl)-piperazin-1- yl][1,3,5]triazin-2-yl}-(R) ethanol.” Bioorganic & Medicinal Chemistry, 11:4179-4188, 2003
B L Mylari, S J Armento, D A Beebe, E L Conn, J B Coutcher, M S Dina, M T O'Gorman, M C
Linhares, W H Martin, P J Oates, D A Tess, G J Withbroe, and W J Zembrowski, “A Highly Selective,
Non-Hydantoin, Non-Carboxylic Acid Inhibitor of Aldose Reductase with Potent Oral Activity in
Diabetic Rat Models: 6-(5-chloro-3-methylbenzofuran- 2-sulfonyl)-2-H-pyridazin-3-one.” Journal of
Medicinal Chemistry, 46:2283-2286, 2003
T A Pauly, J L Ekstrom, D A Beebe, B Chrunyk, D Cunningham, M Griffor, A Kamath, S E Lee, R
Madura, D McGuire, T Subashi, D Wasilko, P Watts, B L Mylari, P J Oates, P D Adams, V L Rath,
“X-Ray Crystallographic and Kinetic Studies of Human Sorbitol Dehydrogenase.” Structure
(Cambridge), 11:1071-85, 2003
A D Hodgkinson, T Bartlett, P J Oates, B A Millward and A G Demaine. “Abnormal Antioxidant
Enzyme Gene Expression in Patients with Type I Diabetes Mellitus and Nephropathy.” Diabetes, 52:846851, 2003
17
P. J. Oates

18. B L Mylari, P J Oates, W J Zembrowski, D A Beebe, E L Conn, J B Coutcher, M T O'Gorman, M C
Linhares and G J Withbroe. “A Sorbitol Dehydrogenase Inhibitor of Exceptional in Vivo Potency with a
Long Duration of Action: 1-(R)-{4-[4-(4,6-Dimethyl[1,3,5]Triazin-2-Yl)- 2R,6R-Dimethylpiperazin-1yl]Pyrimidin-2- yl}Ethanol.” Journal of Medicinal Chemistry, 45: 4398-4401, 2002
M Y Chu-Moyer, W E Ballinger, D A Beebe, J B Coutcher, W W Day, J Li, P J Oates and R M Weekly.
“SAR and Species/Stereo-Selective Metabolism of the Sorbitol Dehydrogenase Inhibitor, CP-470,711.”
Bioorganic and Medicinal Chemistry Letters, 12: 1477-1480, 2002
Y C Hwang, S Sato, J-Y Tsai, S D Yan, S Bakr, H Zhang, P J Oates and R Ramasamy, “Aldose reductase
activation is a key component of myocardial response to ischemia.” FASEB Journal, 16: 243-245, 2002
S Gupta, E Chough, J Daley, P J Oates, K Tornheim, N B Ruderman and J F Keaney, Jr.,
“Hyperglycemia Increases Superoxide Anion in Rabbit Endothelium Leading to Decreased Smooth
Muscle Cell Na+-K+-ATPase Activity.” American Journal of Physiology Cell Physiology, 282:C560C566, 2002
M Y Chu-Moyer, W E Ballinger, D A. Beebe, R Berger, J B Coutcher, W W Day, J Li, B L Mylari, P J
Oates, R M Weekly, “Orally-Effective, Long-Acting Sorbitol Dehydrogenase Inhibitors (SDIs):
Synthesis, Structure-Activity Relationships, and In Vivo Evaluations of Novel Heterocycle-Substituted
Piperazino-Pyrimidines.” Journal of Medicinal Chemistry, 45: 511-528, 2002
B L Mylari, P J Oates, D A Beebe, N S Brackett, J B Coutcher, M S Dina, W J Zembrowski, “Sorbitol
dehydrogenase inhibitors (SDIs): A new potent, enantiomeric SDI, 4-[2-1R-hydroxy-ethyl)-pyrimidin-4yl]-piperazine-1-sulfonic acid dimethylamide.” Journal of Medicinal Chemistry, 44: 2695-2700, 2001
W R Tracey, W P Magee, C A Ellery, J T MacAndrew, A H Smith, D R Knight and P J Oates. “Aldose
Reductase Inhibition Alone or in Combination with an Adenosine A3 Receptor Agonist Reduces
Ischemic Myocardial Injury.” American Journal of Physiology, 279:H1447-H1452, 2000
T W Siegel, S R Smith, C A Ellery, J R Williamson and P J Oates. “An Enzymatic Fluorometric Assay
for Fructose.” Analytical Biochemistry, 280: 329-331, 2000
T Nishikawa, D Edelstein, X L Du, S Yamagishi, T Matsumura, Y Kaneda, M A Yorek, D Beebe, P J
Oates, H-P Hammes, I Giardino and M Brownlee. “Normalizing Mitochondrial Superoxide Production
Blocks Three Pathways of Hyperglycaemic Damage.” Nature, 404: 787-790, 2000
R Ramasamy, H Liu, P J Oates, S Schaefer. “Attenuation of Ischemia Induced Increases in Sodium and
Calcium by the Aldose Reductase Inhibitor Zopolrestat.” Cardiovascular Research, 42: 130-139, 1999
R Ramasamy, P Oates and S Schaefer. “Aldose Reductase Inhibition Protects Diabetic and Non-Diabetic
Rat Hearts From Ischemic Injury.” Diabetes, 42: 292-300, 1997
P Xia, T Inogouchi, T S Kern, R L Engerman, P J Oates and G L King. “Characterization of the
Mechanism for the Chronic Activation of DAG-PKC Pathway in Diabetes and Hypergalactosemia.”
Diabetes, 43: 1122-1129, 1994
G Pugliese, R G Tilton, A Speedy, P J Oates and J R Williamson. “Effects of Combined Insulin and
Sorbinil Treatment on Diabetes-Induced Vascular Dysfunction in Rats.” Metabolism, 43: 492-500, 1994
18
P. J. Oates

19. E M Gibbs, S C McCoid, H K Ortmeyer, R W Stevenson, P J Oates, C A Ellery, D A Beebe and B C
Hansen. “Altered Expression of the Facilitative Fructose/Glucose Transporter (GLUT 5) in the
Development of Diabetes.” Experimental and Clinical Endocrinology, 101 (Suppl. 2): 214-217, 1993
B Tesfamariam, S Gupta, P J Oates, N B Ruderman and R A Cohen. “Reduced Na+/K+ Pump Activity
in Diabetic Rabbit Carotid Artery: Reversal by Aldose Reductase Inhibition.” American Journal of
Physiology, 265 (Heart Circ. Physiol. 34): H1189-H1194, 1993
W R Meyer, M B Doyle, J A Grifo, K J Lipetz, P J Oates, A H DeCherney, M P Diamond. “Aldose
Reductase Inhibition Prevents Galactose-Induced Ovarian Dysfunction in the Sprague-Dawley Rat.”
American Journal of Obstetrics and Gynecology, 167: 1837-43, 1992
H Trachtman, S Futterweit, E Hammer, T W Siegel and P J Oates. “The Role of Polyols in Cerebral Cell
Volume Regulation in Hypernatremic and Hyponatremic States.” Life Sciences, 49: 677-88, 1991
J P Hakkinen, W F Holt, C J Goddard, P J Oates, W R Murphy, J J Maciejko and L A Reiter. “CP66,948: An Antisecretory Histamine H2-Receptor Antagonist with Mucosal Protective Properties.”
Digestive Diseases and Sciences, 36: 1721-28, 1991
P J Oates and J P Hakkinen. “Studies on the Mechanism of Ethanol-Induced Gastric Damage in Rats.”
Gastroenterology, 94: 10-21, 1988, with an accompanying editorial
C A Lipinski, J L LaMattina and P J Oates. “Bioisosteric Prototype Design of Biaryl Imidazoyl and
Triazolyl Competitive H2-Receptor Antagonists.” Journal of Medicinal Chemistry, 29: 2154-2163, 1986
P J Oates and O Touster. “In Vitro Fusion of Acanthamoeba Phagolysosomes. III. Evidence that Cyclic
Nucleotides and Vacuole Subpopulations Respectively Control the Rate and Extent of Vacuole Fusion in
Acanthamoeba Homogenates.” Journal of Cell Biology, 85: 804-810, 1980
P J Oates and O Touster. “In Vitro Fusion of Acanthamoeba Phagolysosomes. II. Quantitative
Characterization of In Vitro Vacuole Fusion by Improved Electron Microscopic and New Light
Microscopic Techniques.” Journal of Cell Biology, 79: 217-234, 1978
P J Oates and O Touster. “In Vitro Fusion of Acanthamoeba Phagolysosomes. I. Demonstration and
Quantitation of Vacuole Fusion in Acanthamoeba Homogenates.” Journal of Cell Biology, 68: 319-338,
1976

Abstracts
P J Oates, S S Klioze, P F Schwartz, A D Boland and The Zopolrestat Diabetic Nephropathy Study
Group, “Aldose Reductase Inhibitor Zopolrestat Reduces Elevated Urinary Albumin Excretion Rate in
Type 1 Diabetes Mellitus Subjects with Incipient Diabetic Nephropathy,” Journal of the American
Society of Nephrology,19:642A, 2008
P J Oates, S S Klioze and The Zopolrestat Diabetic Neuropathy Study Group, “Chronic Treatment with
Aldose Reductase Inhibitor Zopolrestat Suppressed Sorbitol, But Not Fructose, in Sural Nerves of
Patients with Diabetic Neuropathy,” Diabetologia, 50 (Suppl. 1): S62, 2007
R B Burrows and P J Oates, “A Computer Model of Glucose Metabolism.” Diabetic Complications
2007: The Role of Aldose Reductase and Related Pathways, Program, p. 60, 2007
19
P. J. Oates

20. W Sun, P J Oates, J B Coutcher, C Gerhardinger and M Lorenzi, “A Selective Aldose Reductase
Inhibitor of a New Structural Class Prevents or Reverses Early Retinal Abnormalities in Experimental
Diabetic Retinopathy.” Diabetic Complications 2007: The Role of Aldose Reductase and Related
Pathways, Program, p. 51, 2007
J Minchenko, B Bennetts, A Chan, M Craig, P J Oates and K C Donaghue, “Aldose Reductase Gene
Expression In PBMC’s And Genotyping Of Adolescent Patients With Long Duration Of Type 1
Diabetes.”Diabetic Complications 2007: The Role of Aldose Reductase and Related Pathways, Program,
p. 26, 2007
B Yang, A D Hodgkinson, P J Oates, H M Kwon, B A Millward and A G Demaine, “Elevated Activity of
Transcription Factor Nuclear Factor of Activated T-cells 5 (NFAT5) and Diabetic Nephropathy.”
Diabetic Complications 2007: The Role of Aldose Reductase and Related Pathways, Program, p. 25,
2007
K Thamotharampillai, A K F Chan, B Bennetts, M Craig, J Cusumano, M Silink, P J Oates and K C
Donaghue, “Decline in Neurophysiological Function After 7 Years in an Adolescent Diabetic Cohort and
the Role of Aldose Reductase Gene Polymorphisms.” Diabetic Complications 2007: The Role of Aldose
Reductase and Related Pathways, Program, p. 24, 2007
Y Ido, R Tilton, B Mylari, P Oates and J Williamson, “Vascular And Neural Dysfunction In Early
Diabetes Are Largely Sequelae Of Metabolic Imbalances Fueled By Cytosolic Nadh Generated By
Sorbitol Oxidation,” Diabetic Complications 2007: The Role of Aldose Reductase and Related Pathways,
Program, p. 13, 2007
P Oates, “Diabetic Complications and the Polyol Pathway: A New Paradigm.” Pennington Biomedical
Research Symposium, Diabetic Complications, Program, p. 17, 2007
P Oates, D Beebe, C Ellery and J Coutcher, “Normalization of Oxidative Stress Marker GSSG/GSH in
Diabetic Rat Nerve Requires Stronger Aldose Reductase Inhibition Than Normalization of Sorbitol or
Fructose.” Diabetic Medicine, 23 (Suppl. 4):107, 2006
P Oates, D Beebe and C Ellery, “Inhibition of Aldose Reductase Improves the Ratio of Oxidized
Glutathione to Reduced Glutathione in the Blood of Diabetic Rats.” Diabetes, 55 (Suppl. 1):A173, 2006
P Oates, C Ellery, D Beebe, J Coutcher, Y-Z Qian, V Lowe and S O'Neill, “Reduction of Elevated
Urinary Albumin Excretion in Diabetic Rats by Polyol Pathway Inhibitors Correlates with Changes in
Urinary Sorbitol Excretion.” Diabetes, 54 (Suppl. 1):A195, 2005
K F Wright, D Beebe, C Ellery, J Coutcher, C Xie, R Calle and G Preston, “Characterization of a
Reliable Method for Determining Sorbitol Dehydrogenase Activity in Human and Rat Erythrocytes.”
Diabetes, 54 (Suppl. 1):A115, 2005
P Oates, C Ellery, D Beebe, J Coutcher, Y-Z Qian, D Phillips, V Lowe, T Appleton, D Raunig, S O'Neil,
B Mylari, “Sorbitol Dehydrogenase Inhibition As Well As Aldose Reductase Inhibition Prevents
Elevation Of Urinary Albumin Excretion In Diabetic Rats.” Diabetologia, 47 (Suppl. 1): A398, 2004
J Y Yang, X Wu, F L Chau, S C F Tam, P J Oates, S K Chung, S S M Chung, “Blocking the Polyol
Pathway Protects Diabetic Mice Against Hypertriglyceridemia.” Diabetes, 53 (Suppl. 2): A538, 2004
20
P. J. Oates

21. J Coutcher, C Ellery, Y-Z Qian, D Phillips, V Lowe, T Appleton, D Beebe, D Raunig, B Mylari, S
O’Neil and P Oates, “Oral Activity Profile of Aldose Reductase Inhibitor CP-744809 in StreptozocinDiabetic Rats.” International Polyol Pathway Conference Proceedings, p. 65, 2004
D Beebe, P Oates and B Mylari, “Determination of The Equilibrium Dissociation Constant of Aldose
Reductase Inhibitor CP-744809 for Human Aldose Reductase.” International Polyol Pathway Conference
proceedings, International Polyol Pathway Conference Proceedings, p. 64, 2004
K Wright, P Oates, D Beebe, C Ellery and G Preston, “Inhibition of Human Red Blood Cell Sorbitol
Dehydrogenase by CP-470711.” International Polyol Pathway Conference Proceedings, p. 63, 2004
P Oates, “Future Directions in Diabetic Complications Research.” International Polyol Pathway
Conference Proceedings, p. 57, 2004
A K Changolkar, J Hypolite, M E DiSanto, P J Oates, A J Wei, and S Chacko, “Decreased Force
Generation, Polyol Pathway Hyperactivity, and Oxidative Stress In Urinary Bladder Smooth Muscle in
Diabetes.” International Polyol Pathway Conference Proceedings, p. 31, 2004
S Chung, J Yang, P Oates and S Chung, “Polyol Pathway Is a Thrifty Metabolic Pathway That Enhances
Energy Storage In Times of Plenty.” International Polyol Pathway Conference Proceedings, p. 25, 2004
A Hodgkinson, T Bartlett , P Oates, A Millward, A Demaine, “The Effect of Partial and Total Inhibition
of The Polyol Pathway on Expression of Antioxidant, Aldose Reductase and Sorbitol Dehydrogenase
Genes In Patients with Type 1 Diabetes and Diabetic Nephropathy.” International Polyol Pathway
Conference Proceedings, p. 23, 2004
P Oates, J Coutcher, C Ellery, Y-Z Qian, D Phillips, V Lowe, T Appleton, D Beebe, D Raunig, S O’Neil
and B Mylari. “In Vitro and Oral Activity of Sorbitol Dehydrogenase Inhibitor CP-642931 in
Streptozocin Diabetic Rats.” International Polyol Pathway Conference Proceedings, p. 22, 2004
T A Pauly, J L Ekstrom, D A Beebe, B Chrunyk, D Cunningham, M Griffor, A Kamath, S E Lee, R
Madura, D Mcguire, T Subashi, D Wasilko, P Watts, B L Mylari, P J Oates, P D Adams, V L Rath,
“X-Ray Crystallographic and Kinetic Studies of Human Sorbitol Dehydrogenase.” International Polyol
Pathway Conference Proceedings, p. 21, 2004
P J Oates, D A Beebe, J B Coutcher, C A Ellery, and The Zopolrestat Diabetic Neuropathy Study Group,
“Models of Normal and Neuropathic Diabetic Human Sural Nerves and Their Sorbitol Contents.”
Diabetes, 52 (Suppl. 1):A196, 2003
D M Hegazy, B M Yang, P J Oates, B A Millward, and A G Demaine, “Aldose Reductase Inhibition
Reduces the High Glucose Induced Increase in Nuclear Factor Kappa B Binding Activity in Cells from
Patients with Diabetes Mellitus.” Diabetes, 52 (Suppl. 1):A186, 2003
Y C Hwang, S Bakr, C Ellery, P J Oates, and R Ramasamy, “Sorbitol Dehydrogenase Inhibitors: A Novel
Therapeutic Intervention for Protecting Ischemic Myocardium.” Circulation, 106 (Suppl. 2): 194, 2002
P J Oates, D A Beebe, C A Ellery and J B Coutcher. “Quantitation of Polyol Pathway Enzymes in
Normal and Diabetic Rat Sciatic Nerve.” Diabetologia, 45 (Suppl. 2): A324, 2002
P J Oates. “Pathways of Hyperglycemic Damage and Their Interactions: New Insights.” Diabetes
Research and Clinical Practice, 56 (Suppl. 1): S21, 2002
21
P. J. Oates

22. A D Hodgkinson, T Bartlett, P J Oates, B A Millward and A G Demaine. “Abnormal Antioxidant
Enzyme Gene Expression in Patients with Type I Diabetes Mellitus and Nephropathy.” Diabetes, 51
(Suppl. 2): A190, 2002
P J Oates, James B Coutcher, David A Beebe, Craig A Ellery. “Oxidative Stress Marker Urinary 8Hydroxydeoxyguanosine Is Chronically Elevated in Diabetic Rats.” Diabetes, 51 (Suppl. 2): A182, 2002
P J Oates, Craig A Ellery, James B Coutcher, David A Beebe. “A Metabolic Model of Rat Sciatic Nerve
Sorbitol.” Diabetologia, 44 (Suppl. 1): A296, 2001
P J Oates, Craig A Ellery, James B Coutcher, David A Beebe. “A Metabolic Model of Sorbitol in
Normal and Diabetic Peripheral Nerve.” Diabetes, 50 (Suppl. 2): A188, 2001
A D Hodgkinson, P J Oates, B A Millward and A G Demaine. “Hyperglycaemic Induction of Aldose
Reductase mRNA in Cells from Patients with Diabetic Nephropathy Is Prevented by an Inhibitor of
Aldose Reductase.” Diabetes, 50 (Suppl. 2): A176, 2001
P J Oates and C A Ellery. “Vascular Endothelial Growth Factor Immunoreactivity Is Reduced in Serum
and Plasma from Diabetic Rats Treated with an Aldose Reductase Inhibitor.” Diabetes, 49 (Suppl. 1):
A377, 2000
B L Mylari, P J Oates, W E Ballinger, D A Beebe, J B Coutcher, M S Dina, J P Hakkinen, P D Inskeep,
M W Miller, T M Schelhorn and W J Zembrowski. “Sorbitol Dehydrogenase Inhibitors (SDIs): A New
Potent, Enantiomeric SDI, 4-[2-1R Hydroxy-Ethyl)-Pyridin-4-YL]-pPiperazine-1-Sulfonic Acid
Dimethylamide.” US-Japan Aldose Reductase Workshop Proceedings, p. 62, 2000
C A Ellery and P J Oates. “Reversal of Galactose-Induced Renal Hyperperfusion in Rats by Aldose
Reductase Inhibitor Zopolrestat.” Diabetes, 48 (Suppl. 1): A376, 1999
T Nishikawa, D Edelstein, I Giardino, D Beebe, P J Oates, and M Brownlee. “Reversal of
Hyperglycemia-Induced PKC Activation, Intracellular AGE Formation, and Sorbitol Accumulation by
Inhibition of Electron Transport Complex II.” Diabetes, 48 (Suppl. 1): A73, 1999
Y Ido, K Chang, P J Oates, B L Mylari, and J R Williamson. “Inhibitors of Sorbitol Dehydrogenase
(SDI) and Aldose Reductase (ARI) Reverse Impaired Motor Nerve Conduction Velocity (MNCV) in
Diabetic Rats.” Diabetes, 48 (Suppl. 1): A150, 1999
P Oates, T Schelhorn, M Miller, E Hammerlund, C Ellery, D Beebe and J Hakkinen. “Polyol Pathway
Inhibitors Dose-Dependently Preserve Nerve Function In Diabetic Rats.” Diabetologia, 41 (Suppl. 1):
A271, 1998
P Oates and C Ellery, “Alond™ Reduces High Urinary Albumin Excretion But Not Blood Pressure in
Conscious Diabetic Rats.” Diabetologia, 40 (Suppl. 1): A516, 1997
Y Ido, E Ostrow, B Mylari, P Oates and J Williamson. “Decreased Motor Nerve Conduction Velocity
(MNCV) in Diabetic Rats Is Linked to Cytosolic Reductive Stress.” Diabetologia, 40 (Suppl. 1): A33,
1997
22
P. J. Oates

23. I G Obrovsova, J H Burgan, E Ostrow and P J Oates. “Evaluation Of Structurally Different ARIs,
Tolrestat And Sorbinil, vs. SDI On Diabetes-Induced Changes In Lens Metabolism.” Investigative
Ophthalmology & Visual Sciences, 38: S1171, 1997
P Oates and C Ellery. “Mean Arterial Pressure in Conscious Diabetic Rats Is Unaffected by
Zopolrestat.” Diabetes, 46 (Suppl. 1): 335A, 1997
P J Oates, D A Beebe and B L Mylari. “Sorbitol Dehydrogenase Catalysis and Inhibition by CP-166,572:
Ligand Binding and Kinetic Studies.” US–Japan Aldose Reductase Workshop Proceedings, p. 71, 1997
Y Ido, J Burgan, B Mylari, P Oates and J. Williamson. “Comparison of Effects of Inhibition of Sorbitol
Dehydrogenase vs. Aldose Reductase on Peripheral Nerve Electrophysiological Dysfunction in Diabetic
Rats.” US–Japan Aldose Reductase Workshop Proceedings, p. 49, 1997
N Ravi, Y Ido, K Chang, B Mylari, P Oates and J Williamson. “Effects of Inhibition of Sorbitol
Dehydrogenase vs. Aldose Reductase Cataractogenesis in Diabetic Rats.” US–Japan Aldose Reductase
Workshop Proceedings, p. 63, 1997
J Williamson, K Chang, P Oates and Y Ido. “Sorbinil Improves Impaired Neural Hyperemic Responses
to Surgical Trauma in Diabetic Rats.” US–Japan Aldose Reductase Workshop Proceedings, p. 40, 1997
P J Oates, T Nakano, J M Petrash, J R Williamson and I Obrosova. “Glycolytic Pathway, Redox State of
NAD-Couples, and Energy Metabolism in Lenses in Rats with Short-Term Diabetes.” Diabetologia, 39
(Suppl. 1): A54, 1996
Y Ido, P J Oates, B L Mylari, J Burgan, M Bache, A P Mizisin and J R Williamson. “Inhibitors of
Sorbitol Dehydrogenase and Aldose Reductase Prevent Decreased MNCV Caused by Diabetes.”
Diabetologia, 39 (Suppl. 1): A248, 1996
P J Oates, J B Coutcher, and B L Mylari. “The Effect Of Sorbitol Dehydrogenase Inhibition On Sugar
Cataract Formation In Cultured Rat Lens.” Investigative Ophthalmology & Visual Science, 37(3): S190,
1996
I Obrosova, P J Oates, J Burgan and J R Williamson. “Glycolytic Pathway, Redox State of NADcouples and Energy Metabolism in Lens in Rats with Short-Term Streptozotocin Diabetes.” Diabetes,
45:195A, 1996
P Oates, B Mylari, K Chang, and J Williamson. “Inhibition of Sorbitol Dehydrogenase Prevents
Increased Retinal Vascular Albumin Permeation in Diabetic But Not in Galactosemic Rats.”
Investigative Ophthalmology & Visual Science, 36 (4): S1066, 1995
Y Ido, P Oates, B Mylari, D Beebe, J Coutcher, W Zembrowski and J Williamson. “Effects of Sorbitol
Dehydrogenase Inhibition on Peripheral Nerve Conduction and Vascular Function in Control and
Diabetic Rats.” Diabetes, 44 (Suppl. 1): 66A, 1995
R Ramasamy, S Schaefer, P Oates. “Improved Ischemic Tolerance in Diabetic Hearts Treated with an
Aldose Reductase Inhibitor.” Diabetes, 44 (Suppl. 1): 192A, 1995
P Oates, Y Ido, B Mylari, and J Williamson. “Peripheral Neuropathy In Diabetic Rats Is Prevented By
Inhibition Of Sorbitol Dehydrogenase Or Aldose Reductase.” Diabetologia, 38 (Suppl. 1): A232, 1995
23
P. J. Oates

24. J Nyengaard, P Oates, B Mylari, and J Williamson. “Inhibition Of Sorbitol Dehydrogenase Prevents
Reductive Stress Caused By Glucose And Sorbitol But Not Galactose.” Diabetologia, 38 (Suppl. 1):
A276, 1995
Y Ido, K Chang, B Mylari, P Oates, and J Williamson. “Inhibition Of Aldose Reductase Prevents
Hyperperfusion In Surgically-Exposed Sciatic Nerve Of Galactose-Fed Rats.” Diabetologia, 38 (Suppl.
1): A232, 1995
I Obrosova, P J Oates, J Burgan and J R Williamson. “Glycolytic Pathway, Redox State of NADCouples and Energy Metabolism in Lens in Rats with Short-Term Streptozotocin Diabetes.” U.S.-Japan
Cooperative Cataract Research Group Conference Proceedings, November 15-19, 1995
P Oates, J Williamson, K Chang, B Mylari, D Beebe, J Coutcher, T Siegel, and W Zembrowski.
“Attenuation of Diabetes-Induced Vascular Dysfunction by an Inhibitor of Sorbitol Dehydrogenase.”
Diabetes, 43 (Suppl. 1): 17A, 1994
C Ellery and P Oates. “Reversal of Albuminuria in Diabetic Rats by Aldose Reductase Inhibitor
Zopolrestat.” Diabetes, 43 (Suppl. 1): 204A, 1994
J Williamson, K Chang, P Oates, B Mylari, D Beebe, J Coutcher, T Siegel, and W Zembrowski.
“Diabetes-Induced Vascular Dysfunction Is Prevented by Inhibition of Sorbitol Dehydrogenase.”
Diabetologia, 37 (Suppl. 1): A23, 1994
J Williamson, Y Ido, C Kilo, K Chang, B Mylari and P Oates. “Oxidative Stress, Reductive Stress,
Osmotic Stress and Sorbitol Pathway Metabolism.” 15th International Diabetes Federation Congress
Abstracts: 30, 1994
P Oates, B Mylari, K Chang, D Beebe, J Coutcher, T Siegel, W Zembrowski and J Williamson.
“Diabetes-Induced Vascular Dysfunction Is Prevented by Inhibition of Sorbitol Dehydrogenase.” 15th
International Diabetes Federation Congress Abstracts: 373, 1994
L S Norris, T M Schelhorn, P J Oates and A L Rauch. “Losartan (DuP753) Reduces Increased Aortic
DNA Synthesis in Spontaneously Hypertensive Rats.” FASEB Journal, 7: A339, 1993
P J Oates, C A Ellery, K M Davis, D N Guzzie, and P B Inskeep. “Aldose Reductase Inhibitor
Zopolrestat Dose-Dependently Reduces Albuminuria in Streptozocin-Diabetic Rats.” Diabetes, 42
(Suppl. 1): 157A, 1993
P J Oates, C A Ellery and S Goldfarb. “Hyperfiltration and Albuminuria Are Dose-Dependently
Reduced in Diabetic Rats by Zopolrestat.” Diabetologia, 36 (Suppl. 1): A221, 1993
P J Oates and C A Ellery. “Aldose Reductase Inhibitor Zopolrestat Prevents Elevated Urinary Albumin
Excretion in Diabetic Rats.” Diabetes, 41 (Suppl. 1): 121A, 1992
P J Oates, C A Ellery and S Goldfarb. “Aldose Reductase Inhibitor Zopolrestat Reduces Hyperfiltration
and Albuminuria in Diabetic Rats.” Diabetologia, 35 (Suppl. 1): A148, 1992
P J Oates, C A Ellery, L R Pustilnik, P B Inskeep, A E Reed, T A Beyer and N J Hutson. “Zopolrestat
Dose-Dependently Inhibits Renal Hyperperfusion in Galactosemic Rats.” Diabetes, 40 (Suppl. 1): 131A,
1991
24
P. J. Oates

25. P J Oates and C A Ellery. “Measurement of Blood Flow in the Superficial Renal Cortex of Normal and
Galactose-Fed Rats by Laser Doppler Flowmetry.” Kidney International, 37: 554, 1990
P J Oates and L R Pustilnik. “Sorbinil Prevents Galactose-Induced Renal Hyperperfusion.” FASEB
Journal, 4: A437, 1990
P J Oates and C A Ellery. “Aldose Reductase Inhibitors Sorbinil and Zopolrestat Prevent GalactoseInduced Hyperperfusion in the Renal Cortex.” Diabetes, 39 (Suppl. 1): 184A, 1990
P J Oates, C A Ellery and L R Pustilnik. “Renal Hyperperfusion in 30% Galactose-Fed Rats Is Prevented
By Two Structurally Distinct Aldose Reductase Inhibitors.” Diabetologia, 33 (Suppl.): A65, 1990
P J Oates and K J Goddu.
Proceedings 46: 346, 1987
“Sorbitol Distribution Within the Renal Inner Medulla.”
Federation
P J Oates and K J Goddu. “A Sorbitol Gradient in the Rat Renal Medulla.” Kidney International, 31:
448, 1987
P J Oates, C A Lipinski, G M Frame, J L LaMattina and M G Page. “CP-57,361: A Novel Long-Acting
Histamine H2-Antagonist.” Gastroenterology, 88: 1520, 1985
J P Hakkinen and P J Oates. “Microvascular Responses to Concentrated Intragastric Ethanol in Rats.”
Gastroenterology, 86: 1104, 1984
P J Oates, P L Gaudreau and D E Wilder. “Histological Assessment of Gastric Protection by 16,16Dimethyl Prostaglandin E2 in Rats.” C.U.R.E. Symposium, Protective Actions of Prostaglandins in
Gastrointestinal Mucosa, Santa Monica, CA, Jan. 23-24, 1981, p. 19, 1981
P J Oates. “Evidence for a Role of Cyclic Nucleotides in the Lysosome Fusion Process.” Federation
Proceedings, 38: 579, 1979
P J Oates. “Quantitative Studies of In Vitro Phagolysosome Fusion.” Journal of Cell Biology, 75: 197a,
1977
P J Oates. “An Improved Method of Specimen Preparation for TEM.” Journal of Cell Biology, 75:
244a, 1977
P J Oates and O Touster. “Demonstration of In Vitro Fusion of Phagolysosomes in Homogenates of
Acanthamoeba, sp.” Federation Proceedings, 34: 858, 1975
Updated October 17, 2013
25
P. J. Oates